ATE459625T1 - Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het - Google Patents
Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g hetInfo
- Publication number
- ATE459625T1 ATE459625T1 AT99929394T AT99929394T ATE459625T1 AT E459625 T1 ATE459625 T1 AT E459625T1 AT 99929394 T AT99929394 T AT 99929394T AT 99929394 T AT99929394 T AT 99929394T AT E459625 T1 ATE459625 T1 AT E459625T1
- Authority
- AT
- Austria
- Prior art keywords
- het
- protein
- treatment
- production
- medicinal product
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9808731A FR2780974B1 (fr) | 1998-07-08 | 1998-07-08 | Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique |
PCT/FR1999/001609 WO2000002881A2 (fr) | 1998-07-08 | 1999-07-05 | Utilisation de derives de la cysteine pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimerique |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE459625T1 true ATE459625T1 (de) | 2010-03-15 |
Family
ID=9528405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99929394T ATE459625T1 (de) | 1998-07-08 | 1999-07-05 | Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het |
Country Status (17)
Country | Link |
---|---|
US (3) | US6544995B1 (de) |
EP (1) | EP1100801B1 (de) |
JP (1) | JP2002520327A (de) |
AR (1) | AR019908A1 (de) |
AT (1) | ATE459625T1 (de) |
AU (1) | AU756268B2 (de) |
CA (1) | CA2336846C (de) |
DE (1) | DE69942095D1 (de) |
ES (1) | ES2341404T3 (de) |
FR (1) | FR2780974B1 (de) |
MY (1) | MY122419A (de) |
NO (1) | NO319633B1 (de) |
NZ (1) | NZ509789A (de) |
RU (1) | RU2268889C2 (de) |
TW (1) | TW561156B (de) |
WO (1) | WO2000002881A2 (de) |
ZA (1) | ZA200101061B (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2780974B1 (fr) * | 1998-07-08 | 2001-09-28 | Sod Conseils Rech Applic | Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique |
US7084135B1 (en) | 1998-12-31 | 2006-08-01 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Prenyl transferase inhibitors |
DE69915514T2 (de) | 1998-12-31 | 2005-01-05 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Prenyltransferase-inhibitoren |
DE10164711A1 (de) * | 2001-03-13 | 2002-10-17 | Schebo Biotech Ag | Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen |
DE10112925A1 (de) * | 2001-03-13 | 2002-10-02 | Erich Eigenbrodt | Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren, Aminosäureanalogen zur Modulation von Transaminasen und/oder der Assoziation p36/Malat Dehydrogenase |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US20060052382A1 (en) * | 2002-12-20 | 2006-03-09 | Duffy Joseph L | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
FR2879460B1 (fr) * | 2004-12-17 | 2007-02-23 | Sod Conseils Rech Applic | Associations anti-douleur comprenant un derive de dihydroimidazopyrazine |
FR2921658A1 (fr) * | 2007-09-27 | 2009-04-03 | Sod Conseils Rech Applic | Derives des pyrazolo-pyrazines comme inhibiteurs de proteines g |
CN101824036A (zh) * | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
AR077463A1 (es) | 2009-07-09 | 2011-08-31 | Irm Llc | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias |
CN110691597A (zh) | 2017-04-24 | 2020-01-14 | 诺华股份有限公司 | 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案 |
CN112480122B (zh) * | 2020-11-24 | 2022-03-22 | 中山大学 | 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2075630T3 (es) * | 1991-10-11 | 1995-10-01 | Squibb & Sons Inc | Uso de inhibidores de la proteina-farnesil transferasa para la preparacion de un medicamento para bloquear la transformacion neoplastica de celulas inducidas por oncogenes ras. |
GB9226065D0 (en) * | 1992-12-14 | 1993-02-10 | Ici Plc | Peptides |
US5705686A (en) * | 1993-05-18 | 1998-01-06 | University Of Pittsburgh | Inhibition of farnesyl transferase |
EP0703905A1 (de) * | 1993-06-18 | 1996-04-03 | Merck & Co. Inc. | Inhibitoren von farnesyl-protein transferase |
WO1995030012A1 (en) * | 1994-04-26 | 1995-11-09 | Cadus Pharmaceutical Corporation | Functional expression of mammalian adenylyl cyclase in yeast |
CA2159850A1 (en) * | 1994-11-03 | 1996-05-04 | Yadagiri Pendri | Phosphonosulfonate squalene synthetase inhibitor salts and method |
WO1996021456A1 (en) * | 1995-01-12 | 1996-07-18 | University Of Pittsburgh | Inhibitors of prenyl transferases |
FR2736638B1 (fr) * | 1995-07-12 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
US6673927B2 (en) * | 1996-02-16 | 2004-01-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farnesyl transferase inhibitors |
AU714560B2 (en) * | 1996-04-15 | 2000-01-06 | Trustees Of The University Of Pennsylvania, The | Sensitization of cells to radiation and chemotherapy |
US5935812A (en) * | 1996-09-18 | 1999-08-10 | Incyte Pharmaceuticals, Inc. | Human GTP binding protein gamma-3 |
RU2201931C2 (ru) * | 1996-11-20 | 2003-04-10 | Биомежер Инкорпорэйтед | Ингибиторы фарнезилтрансферазы и способы ингибирования фарнезилтрансферазы |
FR2780974B1 (fr) * | 1998-07-08 | 2001-09-28 | Sod Conseils Rech Applic | Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique |
-
1998
- 1998-07-08 FR FR9808731A patent/FR2780974B1/fr not_active Expired - Fee Related
-
1999
- 1999-07-05 CA CA2336846A patent/CA2336846C/en not_active Expired - Fee Related
- 1999-07-05 AU AU46222/99A patent/AU756268B2/en not_active Ceased
- 1999-07-05 RU RU2001103647/15A patent/RU2268889C2/ru not_active IP Right Cessation
- 1999-07-05 ES ES99929394T patent/ES2341404T3/es not_active Expired - Lifetime
- 1999-07-05 DE DE69942095T patent/DE69942095D1/de not_active Expired - Lifetime
- 1999-07-05 NZ NZ509789A patent/NZ509789A/en not_active IP Right Cessation
- 1999-07-05 AT AT99929394T patent/ATE459625T1/de not_active IP Right Cessation
- 1999-07-05 US US09/743,208 patent/US6544995B1/en not_active Expired - Fee Related
- 1999-07-05 EP EP99929394A patent/EP1100801B1/de not_active Expired - Lifetime
- 1999-07-05 JP JP2000559111A patent/JP2002520327A/ja active Pending
- 1999-07-05 WO PCT/FR1999/001609 patent/WO2000002881A2/fr active IP Right Grant
- 1999-07-07 MY MYPI99002848A patent/MY122419A/en unknown
- 1999-07-08 AR ARP990103337A patent/AR019908A1/es not_active Application Discontinuation
- 1999-07-17 TW TW088111517A patent/TW561156B/zh not_active IP Right Cessation
-
2001
- 2001-01-03 NO NO20010029A patent/NO319633B1/no not_active IP Right Cessation
- 2001-02-07 ZA ZA200101061A patent/ZA200101061B/xx unknown
-
2003
- 2003-02-03 US US10/356,862 patent/US7034025B2/en not_active Expired - Fee Related
-
2005
- 2005-09-09 US US11/222,601 patent/US20060035899A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU4622299A (en) | 2000-02-01 |
ES2341404T3 (es) | 2010-06-18 |
RU2268889C2 (ru) | 2006-01-27 |
MY122419A (en) | 2006-04-29 |
US20060035899A1 (en) | 2006-02-16 |
WO2000002881A2 (fr) | 2000-01-20 |
AR019908A1 (es) | 2002-03-20 |
EP1100801B1 (de) | 2010-03-03 |
CA2336846A1 (en) | 2000-01-20 |
NO20010029L (no) | 2001-01-08 |
CA2336846C (en) | 2010-03-16 |
US20030162786A1 (en) | 2003-08-28 |
AU756268B2 (en) | 2003-01-09 |
JP2002520327A (ja) | 2002-07-09 |
FR2780974A1 (fr) | 2000-01-14 |
WO2000002881A3 (fr) | 2000-03-16 |
ZA200101061B (en) | 2002-10-02 |
NO319633B1 (no) | 2005-09-05 |
US6544995B1 (en) | 2003-04-08 |
US7034025B2 (en) | 2006-04-25 |
NO20010029D0 (no) | 2001-01-03 |
NZ509789A (en) | 2004-01-30 |
FR2780974B1 (fr) | 2001-09-28 |
EP1100801A2 (de) | 2001-05-23 |
TW561156B (en) | 2003-11-11 |
DE69942095D1 (de) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE344253T1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE69921941D1 (de) | Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln | |
DE60004974D1 (de) | Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen | |
DE69922930D1 (de) | N-[(substitutierte fünfgliedrige di- oder triaza-doppeltungesättigter ring)carbonyl]guanidinderivate zur behandlung von ischemie | |
ATE385794T1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
DE69940131D1 (de) | Mittel zur Behandlung von Erkrankungen der Speiseröhre | |
ATE556059T1 (de) | Pyrazolderivate zur behandlung von hiv | |
DE60126321D1 (de) | Gelsystem zur ocularen verabreichung von arzneimitteln | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE459625T1 (de) | Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het | |
ATE384522T1 (de) | Medikamente zur chemotherapeutischen behandlung von erkrankungen | |
ATE292134T1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
ATE269077T1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
DE69841984D1 (de) | Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE50010284D1 (de) | Arzneimittel zur behandlung von bluthochdruck | |
DE60112431D1 (de) | Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments | |
DE60104244D1 (de) | Verfahren zur Herstellung von Amiden | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
ATE522218T1 (de) | Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung | |
ATE273276T1 (de) | Cyclobutendion-derivate zur behandlung von artherosclerose | |
DE60230464D1 (de) | Verfahren und Form zur Herstellung von Tabletten aus heissschmelzbarer Tinte | |
DE69937692D1 (de) | Arzneimittel zur behandlung der hemicrania | |
DE69913380D1 (de) | Zusammensetzung zur behandlung von periodontalen erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |